Table 1.
Characteristics of the overall enrolled patients, divided into Group 1 (patients with previous or occult neoplastic disease) and Group 2 (patients without neoplastic disease).
| Variable | Group 1 N = 31 |
Group 2 N = 402 |
p-Value |
|---|---|---|---|
| Gender | 0.7 | ||
| M | 18 (58%) | 246 (61%) | |
| F | 13 (42%) | 156 (39%) | |
| Age at LTX (y) | 58 (IQR, 41–62) | 50 (IQR, 34−39) | 0.039 |
| Pulmonary Disease | 0.002 | ||
| IPAH | 0 (0%) | 7 (1.7%) | |
| CF | 0 (0%) | 109 (27%) | |
| IPF | 17 (55%) | 160 (40%) | |
| COPD/emphysema | 4 (13%) | 55 (14%) | |
| Bronchiectasis | 2 (6.5%) | 13 (3.2%) | |
| Other a | 8 (26%) | 59 (14%) | |
| Type of LTX | 0.8 | ||
| SLTX | 27 (81%) | 339 (84%) | |
| BLTX | 4 (13%) | 63 (16%) |
a Other end-stage pulmonary diseases included lymphangioleiomiomatosis (LAM), histiocytosis-X, graft-versus-host disease (GVHD), extrinsic allergic alveolitis, sarcoidosis, hemosiderosis, and scleroderma. The data are shown as absolute number (with percentage) for categorical variables and as median (with interquartile range) for continuous variables. IQR: interquartile range; M: males; F: females; IPAH: idiopathic pulmonary arterial hypertension; CF: cystic fibrosis; IPF: idiopathic pulmonary fibrosis; COPD: chronic obstructive pulmonary disease; LTX: lung transplant; SLTX: single-lung transplant; BLTX: bilateral lung transplant, y: years.